{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-024723","form_type":"8-K","ticker":"OWLT","cik":"0001816708","company_name":"Owlet, Inc.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.393940+00:00","generated_at":"2026-06-13T10:11:56.800286+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Owlet announces NYSE acceptance of compliance plan; cure period extended 18 months","bullets":["NYSE accepted Owlet's business plan to regain compliance with continued listing standards under Section 802.01B.","Company has 18-month cure period from April 4, 2023 to meet $50M market cap or stockholders' equity threshold.","1-for-14 reverse stock split effective July 7, 2023 to address minimum $1.00 average closing price requirement.","FDA clearance of BabySat medical pulse-oximetry device cited as growth catalyst."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-024723","json":"https://secwatch.observer/filing/0001628280-23-024723.json","markdown":"https://secwatch.observer/filing/0001628280-23-024723.md","text":"https://secwatch.observer/filing/0001628280-23-024723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816708/000162828023024723/0001628280-23-024723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816708/000162828023024723/owlt-20230711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:11:56.800286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}